Skip to Content
Merck
CN

O2264

ONO-1301

≥98% (HPLC)

Synonym(s):

7,8-Dihydro-5-[(E)-[[α-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C26H24N2O4
CAS Number:
176391-41-6
Molecular Weight:
428.48
UNSPSC Code:
12352200
PubChem Substance ID:
24724561
MDL number:
MFCD00936504

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C26H24N2O4/c29-25(30)18-31-24-13-5-11-22-19(9-4-12-23(22)24)14-16-32-28-26(20-7-2-1-3-8-20)21-10-6-15-27-17-21/h1-3,5-11,13,15,17H,4,12,14,16,18H2,(H,29,30)/b28-26+

SMILES string

OC(=O)COc1cccc2C(CCO\N=C(/c3ccccc3)c4cccnc4)=CCCc12

InChI key

WBBLIRPKRKYMTD-BYCLXTJYSA-N

assay

≥98% (HPLC)

composition

Mixture of E and Z isomers

color

white

mp

147-158 °C (lit.)

solubility

DMSO: 18 mg/mL

storage temp.

−20°C

Gene Information

human ... PTGIR(5739), TBXA2R(6915)

Biochem/physiol Actions

Non-prostanoid prostacyclin mimetic; IP receptor agonist with weak EP3 agonist activity.

Storage Class

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
063K4609

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoichiro Hirata et al.
European journal of pharmacology, 674(2-3), 352-358 (2011-11-19)
ONO-1301, a synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, promotes the production of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) by various cell types. Here, we evaluated the therapeutic efficacy of ONO-1301 in rats with ischemia/reperfusion
Kazuto Nakamura et al.
Clinical science (London, England : 1979), 112(12), 607-616 (2007-02-01)
It has been shown previously that administration of angiogenic growth factors as genes or proteins can augment collateral growth in ischaemic tissues. In the present study, we have investigated the effect of ONO-1301, a synthetic prostacyclin agonist with thromboxane-synthase-inhibitory activity
Mai Hazekawa et al.
The Journal of pharmacy and pharmacology, 64(3), 353-359 (2012-02-09)
ONO-1301 was developed as a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. In this study, we investigated the therapeutic time window of oral ONO-1301 and the effect of a single subcutaneous injection of ONO-1301-loaded poly(lactide-co-glycolide) (PLGA) microspheres (ONO-1301
Jun-ichi Suzuki et al.
International heart journal, 53(1), 64-67 (2012-03-09)
ONO-1301MS is a compound that acts as a prostacyclin agonist with thromboxane A2 synthase inhibitory activity. We investigated the effect of ONO-1301MS on myocardial remodeling in murine cardiac allografts. The hearts of Balb/c mice were transplanted into C3H/He mice (a
Yoichiro Hirata et al.
European journal of pharmacology, 699(1-3), 81-87 (2012-12-12)
Injury to the heart can result in cardiomyocyte hypertrophy, fibrosis, and cell death. Myocarditis sometimes progresses to dilated cardiomyopathy. We previously reported that ONO-1301, a synthetic prostacyclin agonist with thromboxane-synthase inhibitory activity, promotes production of hepatocyte growth factor (HGF) from
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service